ITGB3
ENSG00000259207
Target class
Membrane receptor
Chromosome
17
Approved drugs
3
Clinical candidates (approved and in development)
10
- Approved drugs
- 3
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 10
- Chemical probe available
- Yes
- Target name
- ITGB3
- Gene name
- Integrin subunit beta 3
- Gene symbol
- ITGB3
- Previous gene symbols
- GP3A
- Protein name
- Integrin beta-3 (Platelet membrane glycoprotein IIIa) (GPIIIa) (CD antigen CD61)
- CD61
- GPIIIa
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Integrin beta subunits|Human platelet antigens
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 37
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 59.1
- Tissue specificity (Gini)
- 0.639
- Tissue specificity (tau)
- 0.868
- KEGG gene identifiers
- hsa:3690
- Protein interaction confidence
- 0.8642
- Protein interaction partners
- 125
- R-HSA-114608
- R-HSA-1566948
- R-HSA-210990
- R-HSA-2129379
- R-HSA-216083
- R-HSA-2173789
- R-HSA-3000170
- R-HSA-3000178
- R-HSA-354192
- R-HSA-354194
- R-HSA-372708
- R-HSA-4420097
- R-HSA-445144
- R-HSA-5674135
- R-HSA-6802946
- R-HSA-6802948
- R-HSA-6802952
- R-HSA-6802955
- R-HSA-9649948
- R-HSA-9656223
- R-HSA-9769733
- R-HSA-9856532
- R-HSA-9860927
- End position
- 47313743
- Start position
- 47253827
- Chromosome
- 17
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein . Cell projection, lamellipodium membrane . Cell junction, focal adhesion . Postsynaptic cell membrane
- Single-pass type I membrane protein . Synapse .
- Plasma membrane
- PubMed 20020534
- PubMed 20702409
- PubMed 9195946
- PubMed 35687021
- Tissue specificity (tau)
- 0.867925
- Expression inequality (Gini)
- 0.639415
Expression in transcripts per million
- Artery - Aorta
- 59.1
- Thyroid
- 48.51
- Artery - Tibial
- 43.22
- Artery - Coronary
- 29.93
- Colon - Sigmoid
- 27.58
Expression in transcripts per million
- Artery - Aorta59.1
- Thyroid48.51
- Artery - Tibial43.22
- Artery - Coronary29.93
- Colon - Sigmoid27.58
- Cells - Cultured fibroblasts23.12
- Uterus18.88
- Esophagus - Muscularis17.62
- Fallopian Tube16.58
- Esophagus - Gastroesophageal Junction14.46
- Adipose - Subcutaneous12.72
- Colon - Transverse11.51
- Bladder11.29
- Nerve - Tibial11.16
- Kidney - Cortex10.74
- Cells - EBV-transformed lymphocytes9.98
- Cervix - Endocervix8.62
- Lung8.41
- Cervix - Ectocervix8.04
- Breast - Mammary Tissue7.84
- Kidney - Medulla7.62
- Adipose - Visceral (Omentum)7
- Small Intestine - Terminal Ileum6.58
- Prostate5.35
- Vagina4.37
And 29 more, listed on the interactive page.
- GO:0001938
- GO:0007155
- GO:0007160
- GO:0007229
- GO:0007596
- GO:0010595
- GO:0010745
- GO:0010888
- GO:0010989
- GO:0014909
- GO:0030168
- GO:0030949
- GO:0031589
- GO:0032369
- GO:0033627
- GO:0033631
- GO:0034113
- GO:0034446
- GO:0035295
- GO:0038027
- GO:0042060
- GO:0043277
- GO:0045124
- GO:0046718
- GO:0048333
And 6 more, listed on the interactive page.
- GO:0005634
- GO:0005886
- GO:0005911
- GO:0005925
- GO:0008305
- GO:0009986
- GO:0031092
- GO:0031258
- GO:0031527
- GO:0031528
- GO:0032587
- GO:0032991
- GO:0034683
- GO:0035866
- GO:0035867
- GO:0035868
- GO:0042470
- GO:0043235
- GO:0070062
- GO:0070442
- GO:0071062
- GO:0098978
- GO:0001968
- GO:0002020
- GO:0003756
- GO:0004895
- GO:0005161
- GO:0005178
- GO:0005515
- GO:0015026
- GO:0017134
- GO:0019899
- GO:0019960
- GO:0031994
- GO:0038132
- GO:0042802
- GO:0043184
- GO:0050839
- GO:0050840
Related records
Trials (186)
- A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
- A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
- A Multicenter, Three-Arm, Open-Label, Endpoint-Blinded Randomized Controlled Trial to Evaluate the Optimal Duration of Early Tirofiban After Intravenous Thrombolysis in Acute Ischemic Stroke
- A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
- A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
- A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI
- A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function
- A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
- A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration
- A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
- A Safety Study of Eptifibatide in Patients With Sickle Cell Disease
- A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks
- A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
- A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty
- A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
- A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
- A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
- A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)
Drugs (13)
- Abciximab Integrin alpha-IIb/beta-3 inhibitor
- Abituzumab Integrin alpha-V/beta-3 inhibitor
- ATN-161 Integrin alpha-V/beta-3 antagonist
- Cilengitide Integrin alpha-V/beta-3 antagonist
- Eptifibatide Integrin alpha-IIb/beta-3 inhibitor
- Etaracizumab Integrin alpha-V/beta-3 antagonist
- Intetumumab Integrin alpha-V/beta-3 antagonist
- Risuteganib
- Tadocizumab Integrin alpha-IIb/beta-3 antagonist
- Tirofiban Integrin alpha-IIb/beta-3 inhibitor
- Tirofiban hydrochloride Integrin alpha-IIb/beta-3 inhibitor
- Zalunfiban Integrin alpha-IIb/beta-3 inhibitor
- Zalunfiban acetate Integrin alpha-IIb/beta-3 inhibitor